Tamibarotene (Am80), a selective agonist of RARα, has been shown to exert significant inhibitory effects on neuroinflammation after ischemic stroke and intracranial hemorrhage (ICH) (14–17), thus suggesting the suitability of targeting RARα as a form of stroke therapy. The gene discussed is RARA; the disease is intracranial hemorrhage.